Clinical trials: Beta-Amyloid
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Chronic Plaque Psoriasis
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either…
- Trial name
- NCT00770965
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Psoriasis
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
This is a Phase 2, multicenter, open-label study in subjects with moderate to severe plaque psoriasis aged 6 to 17 years, inclusive, intended to assess the safety, tolerability, and PK of apremilast with 2 weeks of oral…
- Trial name
- NCT02576678
- Testing
- Apremilast
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 42 people
- Sponsor
- Amgen
Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03701763
- Testing
- Apremilast (CC-10004)
- Where
- 99 sites in United States, Belgium and 8 more
- Volunteers
- 245 people
- Sponsor
- Amgen
Plaque Psoriasis
Plaque Psoriasis Study in Pediatric Subjects
The purpose of this study is to compare the safety, efficacy and calcium metabolism of up to 8 weeks of treatment with calcitriol 3 mcg/g ointment versus its vehicle, when used twice daily, without occlusion, to treat children…
- Trial name
- NCT02186665
- Testing
- calcitriol ointment
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 19 people
- Sponsor
- Galderma R&D
Psoriasis
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis.
- Trial name
- NCT01745133
- Testing
- vehicle foam, calcipotriene, calcipotriene + clobetasol propionate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Leon Kircik, M.D.
Psoriasis
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
The purpose of this study is to evaluate the efficacy of adding methotrexate to etanercept compared with etanercept monotherapy as measured by the percentage of participants achieving a 75% improvement from baseline in the…
- Trial name
- NCT01001208
- Testing
- Methotrexate, Etanercept
- Volunteers
- 478 people
- Sponsor
- Amgen
Dental Plaque
Compare the Clinical Efficacy of Prototype Toothpastes
Clinical study to compare the clinical efficacy of toothpastes on dental plaque and gingival inflammation.
- Trial name
- NCT00926029
- Testing
- Fluoride, Triclosan, fluoride, Metal salt
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Chronic Plaque Psoriasis
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.
- Trial name
- NCT00245765
- Testing
- Certolizumab Pegol
- Where
- 15 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- UCB Pharma
Chronic Plaque Psoriasis
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
- Trial name
- DERMIS-OLE (NCT04286607)
- Testing
- Topical roflumilast
- Where
- 85 sites in United States, Canada and 1 more
- Volunteers
- 337 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis
Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis
Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis.
- Trial name
- NCT02201524
- Testing
- PF-04965842
- Where
- 45 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Pfizer
Moderate to Severe Palmoplantar Psoriasis
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.
- Trial name
- GESTURE (NCT01806597)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Dental Plaque
Dental Plaque Removal Ability of Prototype Power Toothbrush Versus a Manual Toothbrush in Healthy Participants
The aim of this study is to evaluate the ability of a prototype power toothbrush (PTB) versus a manual toothbrush in healthy, right-handed manual toothbrush (MTB) participants with no signs of periodontal disease or excessive…
- Trial name
- NCT03809910
- Testing
- Reference MTB, Reference PTB, Prototype PTB (Gum line mode)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 300 (200 AA4500 and 100 placebo) men will be randomized.
- Trial name
- NCT01221623
- Testing
- AA4500
- Where
- 34 sites in United States, Australia
- Volunteers
- 418 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Plaque Psoriasis
Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis
This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis.
- Trial name
- NCT03441789
- Testing
- Enstilar, Vehicle, Otezla
- Where
- 4 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- L.H. Kircik, M.D.
Plaque Psoriasis
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.
- Trial name
- NCT01166646
- Testing
- Halobetasol Proprionate Lotion 0.05%, Halobetasol Proprionate Cream 0.05%
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Therapeutics, Inc.
Psoriasis
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects…
- Trial name
- NCT03718299
- Testing
- Injections of tildrakizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the…
- Trial name
- NCT02310750
- Testing
- PF-06700841 oral solution/suspension, PF-06700841 tablet
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis Vulgaris
A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris
The purpose of the study is to compare the anti-psoriatic effect of marketed products with Daivobet® ointment in a plaque test
- Trial name
- NCT00845481
- Testing
- Daivobet® ointment, Betnovat® ointment, Diprosalic ointment
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma